Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Piotroski F-score
Incyte Corporation's Piotroski F-score for fiscal 2025 is 9 out of 9: 9 of nine tests of profitability, leverage and efficiency passed, up from 5 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 9 | 4.00 |
| FY2024 | 5 | 0.00 |
| FY2023 | 5 | 1.00 |
| FY2022 | 4 | 0.00 |
| FY2021 | 4 | 0.00 |
| FY2020 | 4 | (1.00) |
| FY2019 | 5 | (2.00) |
| FY2018 | 7 | 3.00 |
| FY2017 | 4 | (2.00) |
| FY2016 | 6 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 20.75% | 0.53% | Pass | 1 |
| Positive operating cash flow | 1.41b | 335.34m | Pass | 1 |
| Rising return on assets | 20.75% | 0.53% | Pass | 1 |
| Cash flow above net income | 126.85m | 302.72m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.01 | Pass | 1 |
| Rising current ratio | 3.32 | 1.97 | Pass | 1 |
| No new shares issued | 195,204,000 | 207,110,000 | Pass | 1 |
| Rising gross margin | 92.76% | 92.64% | Pass | 1 |
| Rising asset turnover | 0.83 | 0.69 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 9 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INCY Incyte Corporation | 9 |
| EXEL Exelixis, Inc. compare | 7 |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6 |
| ASND Ascendis Pharma A/S compare | 5 |
| RPRX Royalty Pharma PLC compare | 5 |
| GMAB Genmab A/S Sponsored ADR compare | 4 |
| INSM Insmed, Inc. compare | 4 |
| BNTX BioNTech SE Sponsored ADR compare | 4 |
| ROIV Roivant Sciences Ltd. compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement